Symposia: Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological
Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Clinical trials, Combination therapy, Adult, Epidemiology, Lymphomas, Non-Hodgkin lymphoma, Clinical Practice (Health Services and Quality), Bispecific Antibody Therapy, Translational Research, Drug development, Clinical Research, B Cell lymphoma, Diseases, Indolent lymphoma, Therapy sequence, Treatment Considerations, Biological therapies, Immunotherapy, Lymphoid Malignancies, Biological Processes, Molecular biology, Technology and Procedures, Study Population, Human, Measurable Residual Disease , Transplantation (Allogeneic and Autologous), Molecular testing
Type: Oral
Hematology Disease Topics & Pathways:
Research, Clinical trials, Combination therapy, Adult, Epidemiology, Lymphomas, Non-Hodgkin lymphoma, Clinical Practice (Health Services and Quality), Bispecific Antibody Therapy, Translational Research, Drug development, Clinical Research, B Cell lymphoma, Diseases, Indolent lymphoma, Therapy sequence, Treatment Considerations, Biological therapies, Immunotherapy, Lymphoid Malignancies, Biological Processes, Molecular biology, Technology and Procedures, Study Population, Human, Measurable Residual Disease , Transplantation (Allogeneic and Autologous), Molecular testing
Saturday, December 7, 2024: 4:00 PM-5:30 PM
Marriott Grand Ballroom 11-13
(Marriott Marquis San Diego Marina)
Moderators:
Erika Haydu, MD PhD, Massachusetts General Hospital Cancer Center
and
Dipti Talaulikar, PhD, FRACP, FRCPA, MBBS, Australian National University
Disclosures:
Haydu: Abbvie/Genmab: Consultancy, Research Funding. Talaulikar: Antengene: Honoraria; Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Janssen: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Beigene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Immutep: Current equity holder in publicly-traded company.
Novel treatments for WM and FL are included in the cases of high impact as well as large studies providing new insights into treatments that have been considered standards in the past
4:00 PM
4:15 PM
4:30 PM
4:45 PM
5:00 PM
5:15 PM
See more of: Oral and Poster Abstracts
*signifies non-member of ASH